Get started
Author

Lukas Schollenberger

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
2016 · Markus Moehler, Irina Gepfner-Tuma, et al. · BMC Cancer · 66
PDF
A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial
2023 · Michael Schultheis, Petra Staubach, et al. · British Journal of Dermatology · 15
PDF
FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial.
2013 · Markus Hermann Moehler, Peter C. Thuss-Patience, et al. · Journal of Clinical Oncology · 12
The PROMISE study protocol: a multicenter prospective study of process optimization with interdisciplinary and cross-sectoral care for German patients receiving hip and knee endoprostheses
2020 · Ulrich Betz, Laura Langanki, et al. · Acta Orthopaedica · 9
Drivers of disease severity and burden of hidradenitis suppurativa: a cross‐sectional analysis on 553 German patients
2023 · Michael Schultheis, Stephan Grabbe, et al. · International Journal of Dermatology · 8
PDF
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046
2021 · Slavomir Krajnak, Thomas Decker, et al. · Journal of Cancer Research and Clinical Oncology · 8
PDF
Time-Dependent Prediction Models for Individual Prognosis of Chronic Postsurgical Pain following Knee Replacement Based on an Extensive Multivariable Data Set
2024 · Ulrich Betz, Michael Clarius, et al. · Journal of Clinical Medicine · 3
PDF
A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effective
2023 · Marcus Heise, Petra Staubach, et al. · Journal of Dermatological Treatment · 2
PDF
Feasibility of a Complex Optimized Process for the Treatment of Patients Receiving Hip and Knee Endoprostheses in Most Different Settings in Germany—Results from the PROMISE Trial
2022 · Ulrich Betz, Laura Langanki, et al. · Processes · 2
PDF
Characteristics of children with severe preschool asthma prior to starting the TIPP study
2025 · S. Zielen, J. Wosniok, et al. · Frontiers in Pediatrics · 1
Efficacy and safety of tiotropium in partial and uncontrolled preschool asthma (TIPP): a phase III, multicentre, randomised, double-blind, placebo-controlled trial
2026 · Stefan Zielen, Nadine Wollscheid, et al. · EClinicalMedicine
Eine prospektive Studie zur Untersuchung der Wirksamkeit und Sicherheit von Tiotropium bei partiellem und unkontrolliertem Asthma im Vorschulalter (Tipp).
2026 · S Zielen, N Wollscheid, et al. · Klinische Pädiatrie
How to ESCAPE from Pain? An Observational Study on Improving Pain and Quality of Life with the Cannamedical® Hybrid Cannabis Extract
2025 · Yvonne Wagner, Ines Samel, et al. · Advances in Therapy
PDF
A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effective
2023 · Marcus Heise, Petra Staubach, et al. · Figshare
Eine prospektive, placebo-kontrollierte multizentrische Studie zur Untersuchung der Wirksamkeit und Sicherheit von Tiotropium bei teil- und unkontrolliertem Asthma im Vorschulalter
2022 · J Trischler, H Donath, et al. · Klinische Pädiatrie
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro - AGO-B-046
2021 · S Krajnak, T Decker, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Abstract OT2-05-02: A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro
2018 · M Schmidt, T Decker, et al. · Cancer Research
A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro
2017 · Christoph Thomssen, Thomas Decker, et al. · The Breast
VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy
2017 · T. Elger, T. Decker, et al. · Annals of Oncology
PDF
VinoMetro: phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy
2017 · Slavomir Krajnak, Thomas Decker, et al.
Additional file 1: of Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
2016 · Moehler, Markus, Gepfner-Tuma, Irina, et al. · Figshare
Additional file 2: of Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
2016 · Moehler, Markus, Gepfner-Tuma, Irina, et al. · Figshare
Evaluation von Zelltodmarkern als neue Biomarker bei Patienten mit fortgeschrittenen gastroösophagealen Karzinomen
2015 · J Schattenberg, J Schulz, et al. · Zeitschrift für Gastroenterologie
Prädiktive Bedeutung des Cytokeratin 18 Fragment M30 unter Chemotherapie bei Patienten mit fortgeschrittenen gastroösophageale Karzinomen
2014 · JM Schattenberg, J Schulz, et al. · Zeitschrift für Gastroenterologie
FOLFIRI + Sunitinib versus FOLFIRI allein bei Chemotherapie-refraktären Patienten mit metastasierten ösophagogastralen Karzinomen: Eine randomisierte Placebo-kontrollierte multizentrische Phase II-Studie
2013 · M Möhler, PC Thuss-Patience, et al. · Zeitschrift für Gastroenterologie
Works count: 28
Citation count: 126
H-index: 6
I10-index: 3
Year
Topic
Type